United Pharm (033270) — Capital Reinvestment Ratio
Latest as of March 2026:
0.71x
United Pharm (033270) has a Capital Reinvestment Ratio of 0.71x as of March 2026, meaning it reinvests 1% of its operating cash flow (₩35.58 Billion) in capital expenditures (₩25.34 Billion). See 033270 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.71x
Capex / Operating Cash Flow
Operating Cash Flow
₩35.58 Billion
KRW
Capital Expenditures
₩25.34 Billion
KRW
Data as of
Mar 2026
Most recent filing
United Pharm Capital Reinvestment Ratio (2011–2025)
This chart tracks United Pharm's Capital Reinvestment Ratio across 14 annual periods.
Annual Capital Reinvestment Ratio for United Pharm (2011–2025)
Year-by-year Capital Reinvestment Ratio for United Pharm from 2011 to 2025. For live market cap and broader valuation context, see 033270 market cap overview.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | ₩51.14 Billion | ₩25.14 Billion | ▼ -37.9% |
| 2024 | 0.79x | ₩26.79 Billion | ₩21.22 Billion | ▲ +25.9% |
| 2023 | 0.63x | ₩49.77 Billion | ₩31.31 Billion | ▲ +65.8% |
| 2022 | 0.38x | ₩63.78 Billion | ₩24.21 Billion | ▲ +30.8% |
| 2021 | 0.29x | ₩44.09 Billion | ₩12.79 Billion | ▼ -14.5% |
| 2020 | 0.34x | ₩36.96 Billion | ₩12.55 Billion | ▼ -34.5% |
| 2019 | 0.52x | ₩38.15 Billion | ₩19.76 Billion | ▲ +10.1% |
| 2018 | 0.47x | ₩36.86 Billion | ₩17.35 Billion | ▼ -52.8% |
| 2017 | 1.00x | ₩27.68 Billion | ₩27.59 Billion | ▲ +125.1% |
| 2016 | 0.44x | ₩30.02 Billion | ₩13.29 Billion | ▲ +17.3% |
| 2014 | 0.38x | ₩21.31 Billion | ₩8.05 Billion | ▼ -40.8% |
| 2013 | 0.64x | ₩18.97 Billion | ₩12.11 Billion | ▲ +14.8% |
| 2012 | 0.56x | ₩21.88 Billion | ₩12.16 Billion | ▲ +2.6% |
| 2011 | 0.54x | ₩27.62 Billion | ₩14.95 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow